In the past 5 years DR has acted as a paid consultant to Bayer Schering, Cubist and Curacyte, the pharmaceutical companies who have the potential blood-sparing agents aprotinin under review and Eccallentide and CU 2010 respectively under development.
The withdrawal of marketing approval for aprotinin resulted in more clinicians administering tranexamic acid to patients at increased risk of bleeding and adverse outcome. The latest in a series of retrospective analyses of observational data is published in Critical Care and suggests an increase in mortality, when compared to data from the aprotinin era, in those patients having surgery when a cardiac chamber is opened. The added observation of an increase in cerebral excitatory phenomena (seizure activity) with tranexamic acid has a known mechanism and questions if such patients should be given this drug.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
- Tranexamic acid in cardiac surgery: is there a cause for concern?
- BioMed Central
Neu im Fachgebiet AINS
Meistgelesene Bücher aus dem Fachgebiet AINS
Mail Icon II